Eli Lilly (LLY.US) signs a cooperation agreement with Sangamo BioSciences worth up to $1.2 billion to jointly research RNAi therapy for metabolic diseases.

Zhixin Finance APP learned that Eli Lilly (LLY.US) announced last Saturday that it has reached a global research and development collaboration and licensing agreement with Sanegene Bio, with a total value of up to $1.2 billion, to jointly develop and commercialize RNAi therapy for metabolic diseases.